- Trials with a EudraCT protocol (45)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
45 result(s) found for: pfizer biontech.
Displaying page 2 of 3.
EudraCT Number: 2020-005442-42 | Sponsor Protocol Number: C4591007 | Start Date*: 2021-04-28 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBOCONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A S... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005444-35 | Sponsor Protocol Number: C4591015 | Start Date*: 2021-04-15 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEAL... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: In utero, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005197-25 | Sponsor Protocol Number: C4591031 | Start Date*: 2022-02-22 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162b2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162b2 | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006877-44 | Sponsor Protocol Number: 7081-031 | Start Date*: 2024-01-24 |
Sponsor Name:Fachhochschule Salzburg GmbH | ||
Full Title: Factors influencing SARS-CoV-2 antibody formation | ||
Medical condition: Prevention or lindering of the symtoms in the course of a covid-19 disease due to vaccination with SARS-CoV-2 directed vaccins. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001304-15 | Sponsor Protocol Number: AZGS2021005 | Start Date*: 2021-05-06 |
Sponsor Name:vzw az groeninge | ||
Full Title: COVID-19: Study of the immune response in healthy volunteers after vaccination against SARS-CoV-2 (COVID19-VAX-AZG) and monitoring of breakthrough infections after booster vaccination (COVID19-VAX-... | ||
Medical condition: immuneresponse after vaccination | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001103-32 | Sponsor Protocol Number: HEPCOViVac | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Graz | ||
Full Title: The HEPCOViVac Registry - Immunological response in patients with liver disease vaccinated against COVID-19 | ||
Medical condition: Cirrhotic chronic liver disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003386-35 | Sponsor Protocol Number: INSIGHT-016 | Start Date*: 2021-09-01 | |||||||||||
Sponsor Name:Regents of the University of Minesota | |||||||||||||
Full Title: SARS-CoV-2 vaccination strategies in previous hospitalised and recovered COVID-19 patients | |||||||||||||
Medical condition: Participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sus... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001290-23 | Sponsor Protocol Number: C4591024 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000440-22 | Sponsor Protocol Number: Version17032021 | Start Date*: 2021-03-25 |
Sponsor Name:Universiteit Antwerpen | ||
Full Title: Vaccination against COVID-19 in Pregnant and Lactating Women in Belgium | ||
Medical condition: Vaccine responses to COVID19 vaccines administered in pregnant and lactating women | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000206-17 | Sponsor Protocol Number: COVID19_7 | Start Date*: 2021-03-10 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County, with regard to vaccinations. | ||
Medical condition: Vaccination against COVID-19. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002560-73 | Sponsor Protocol Number: SWITCH_ON | Start Date*: 2022-09-01 |
Sponsor Name:Erasmus MC | ||
Full Title: SWITCH ON: Analysing the immunogenicity of additional booster vaccinations in healthcare workers. | ||
Medical condition: To study the necessity to boost healthcare workers (which arre representative for the dutch population) with a COVID vaccin by measuring the immunogenicity at 7 days and 28 days.. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000930-32 | Sponsor Protocol Number: SJ2021005 | Start Date*: 2021-04-27 |
Sponsor Name:AZ Sint-Jan Brugge-Oostende AV | ||
Full Title: COVID-19: Documentation of humoral and cellular immune response of hemodialysis patients after vaccination against SARS-CoV-2 | ||
Medical condition: hemodialysis patients hemodialysis patients with comorbidities | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000880-63 | Sponsor Protocol Number: na | Start Date*: 2021-03-11 |
Sponsor Name:Skåne University Hospital, department of rheumatology in Lud and Malmö | ||
Full Title: COVID-19 vaccine in patients with inflammatory rheumatic diseases: The impact of immunomodulating treatments on the antibody response, T cells response and protection against infection (COVID19-REUMA) | ||
Medical condition: rheumatoid arthritis, SLE, systemic vasculitis, systemic sclerosis, spondylarthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000302-10 | Sponsor Protocol Number: UHKT-COVID19 | Start Date*: 2022-01-24 |
Sponsor Name:Institute of hematology and blood transfusion | ||
Full Title: Significance of T cell response to vaccination against SARS-CoV2 for leukemic patients with weakend immune system | ||
Medical condition: Recipients of cell therapy (allo HSCT, CAR19 T cells) indicated to vaccination against COVID19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003573-58 | Sponsor Protocol Number: 2025 | Start Date*: 2021-08-09 |
Sponsor Name:Antwerp University Hospital | ||
Full Title: Vaccination against cOvid-19 In CancEr: booster shot BNT161b2 vaccine after full vaccination with ChAdOx1-S vaccine (Tri-VOICE plus) | ||
Medical condition: Onco-hematological patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000673-83 | Sponsor Protocol Number: TJB2101 | Start Date*: 2021-03-11 |
Sponsor Name:CHU de Liège | ||
Full Title: Impact of the immune system on response to COVID-19 vaccine in allogeneic stem cell recipients | ||
Medical condition: Allogeneic hematopoietic stem cell recipients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000710-42 | Sponsor Protocol Number: RR-xx-RTX-COVAC | Start Date*: 2021-03-15 | |||||||||||
Sponsor Name:Sint Maartenskliniek | |||||||||||||
Full Title: The RTX-COVAC study: humoral response to COVID-19 vaccination after rituximab, and relation with dose and vaccination timing. A prospective cohort study. | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002571-18 | Sponsor Protocol Number: 170KG18 | Start Date*: 2019-07-22 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: EFFECT OF FERRIC CARBOXYMALTOSE ON EXERCISE CAPACITY AFTER KIDNEY TRANSPLANTATION: A MULTICENTER RANDOMIZED CONTROLLED TRIAL | |||||||||||||
Medical condition: Iron deficiency in kidney transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002530-17 | Sponsor Protocol Number: D7220C00001 | Start Date*: 2021-07-14 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD28... | |||||||||||||
Medical condition: SARS-COV-2 infection (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001459-15 | Sponsor Protocol Number: HS-2021-02 | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Graz | ||
Full Title: Immune response to COVID-19 Vaccination in people with Diabetes Mellitus - COVAC-DM study | ||
Medical condition: Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
